ORIC Pharmaceuticals, Inc.
ORIC
$9.85
$0.232.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.41% | 6.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.40% | -17.32% | |||
| Operating Income | -19.40% | 17.32% | |||
| Income Before Tax | -21.10% | 17.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.10% | 17.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.10% | 17.31% | |||
| EBIT | -19.40% | 17.32% | |||
| EBITDA | -19.55% | 17.45% | |||
| EPS Basic | -10.10% | 17.77% | |||
| Normalized Basic EPS | -10.11% | 17.78% | |||
| EPS Diluted | -10.10% | 17.77% | |||
| Normalized Diluted EPS | -10.11% | 17.78% | |||
| Average Basic Shares Outstanding | 9.97% | 0.55% | |||
| Average Diluted Shares Outstanding | 9.97% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||